/ Dr. Reddy's Gets EIR From USFDA For Miryalaguda Plant ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 14 June 2017

Dr. Reddy’s Laboratories on Tuesday informed the bourses that its API manufacturing facility at Miryalaguda has received an Establishment Inspection Report (EIR) from the US FDA after the closure of audit.

The stock is trading higher by 1.2% at Rs 2,661.50 per share at 1007 hours IST on BSE. It hit a high of Rs 2,681 and a low of Rs 2,647 during the morning session. The market capitalisation of the company is Rs 44,724.48 crore.

The stock has underperformed both BSE Sensex and BSE Healthcare over a period of one year.

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔